EURÓPAI SZABADALOM
SZÖVEGÉNEK FORDÍTÁSA

(21) Magyar ügyszám: E 13 795979
(22) A bejelentés napja: 2013. 11. 18.
(51) Int. Cl.: A61K 47/32 (2006.01)
A61K 31/136 (2006.01)
A61K 31/145 (2006.01)
A61K 31/192 (2006.01)
A61K 47/34 (2006.01)
A61K 47/14 (2006.01)
A61K 47/18 (2006.01)
A61K 9/00 (2006.01)
A61K 47/10 (2006.01)
(96) Az európai bejelentés bejelentési száma:
EP 20130795979
(97) Az európai bejelentés közzétételi adatai:
(97) Az európai szabadalom megadásának meghirdetési adatai:
EP 2922528 B1 2017. 05. 31.
(86) A nemzetközi (PCT) bejelentési szám:
PCT/US 13/070613
(87) A nemzetközi közzétételi szám:
WO 14081674

(30) Elsőbbségi adatok:
201261728403 P 2012. 11. 20. US
201361770768 P 2013. 02. 28. US
(73) Jogosult(ak):
ALLERGAN, INC., Irvine CA 92612 (US)

(72) Feltaláló(k):
WARNER, Kevin S., Anaheim, California 92807 (US)
PARASHAR, Ajay P., Irvine, California 92612 (US)
SWAMINATHAN, Vijaya, Bangalore 560102 (IN)
BHATT, Varsha, San Francisco, California 94123 (US)

(74) Képviselő:
SBGK Szabadalmi Ügyvivői Iroda, Budapest

(54) Topikális dapson és dapson/adapalen készítmények és alkalmazási eljárások
EUROPEAN PATENT SPECIFICATION

Date of publication and mention of the grant of the patent:
31.05.2017 Bulletin 2017/22

Application number: 13795979.7

Date of filing: 18.11.2013

Int Cl.:
A61K 47/32 (2006.01)
A61K 47/14 (2007.01)
A61K 47/34 (2007.01)
A61K 31/192 (2006.01)
A61K 31/136 (2006.01)

International application number:
PCT/US2013/070613

International publication number:
WO 2014/081674 (30.05.2014 Gazette 2014/22)

TOPICAL DAPSONE AND DAPSONE/ADAPALENE COMPOSITIONS AND METHODS FOR USE THEREOF

TOPISCHES DAPSON UND DAPSON-/ADAPALENZUSAMMENSETZUNGEN SOWIE VERFAHREN ZUR VERWENDUNG DAVON

COMPOSITIONS TOPIQUES DE DAPSONE ET DE DAPSONE/ADAPALÈNE ET LEURS MÉTHODES D’UTILISATION

Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB
GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO
PL PT RO RS SE SI SK SM TR

Priority:
20.11.2012 US 201261728403 P
28.02.2013 US 20136177068 P

Date of publication of application:
30.09.2015 Bulletin 2015/40

Proprietor: ALLERGAN, INC.
Irvine, CA 92612 (US)

Inventors:
• WARNER, Kevin S.
Anahiem, California 92807 (US)
• PARASHAR, Ajay P.
Irvine, California 92612 (US)
• SWAMINATHAN, Vijaya
Bangalore 560102 (IN)

• BHATT, Varsha
San Francisco, California 94123 (US)

Representative: Hoffmann Eitle
Patent- und Rechtsanwälte PartmbB
Arabellastraße 30
81925 München (DE)

References cited:
WO-A1-2011/014627

XP005893393, ISSN: 0190-9622, DOI: 10.1016/j.jaad.2006.10.005

Note: Within nine months of the publication of the mention of the grant of the European patent in the European Patent Bulletin, any person may give notice to the European Patent Office of opposition to that patent, in accordance with the Implementing Regulations. Notice of opposition shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).
The present embodiments relate generally to compositions useful for treating a variety of dermatological conditions. In particular, some embodiments relate to dapsone and dapsone/adapalene compositions and methods for use thereof.

Classification and the diagnosis of various acne conditions can be complex, and even contradictory. Given this complexity and unpredictability, medication and other therapies, are often developed on a trial-and-error basis in order to determine the most effective course of treatment for a particular patient. The outcome of any particular acne treatment regimen greatly varies from patient to patient, as well as throughout treatment of a particular patient. In addition to the complexity and variability of acne conditions, treatment efficacy can be greatly affected by a patient's compliance with the treatment regimen. Patient compliance during acne treatment may be influenced by side effects, which, for topical medications, commonly include redness, itching, and skin peeling. The complexity of the drug regimen can also negatively affect patient compliance, particularly where two or more different topical medications are prescribed simultaneously. Another factor that negatively affects patient compliance is the cost of a drug regimen, which is considerably higher when multiple medications are prescribed. In some countries, acne is considered a cosmetic problem, and acne treatments are not covered by insurance plans, thus further increasing a patient's treatment costs. Certain compositions for treatment of acne are available. Many of the available compositions include one active agent known to have anti-acne activity. Stability of compositions with multiple anti-acne agents can be problematic. Also, these compositions can be difficult to manufacture.

The problems described above are not confined to the treatment or acne, but are also applicable to a variety of other skin conditions, including, but not limited, to conditions or classes of conditions with complex or unknown etiology and that are difficult to classify or diagnose, in which, nevertheless, topical application of agents are known to be effective at least in some cases. Examples of such conditions or classes of conditions include psoriasis, rosacea and ichthyosis.

Accordingly, there is a continuing need for compositions and methods used in a treatment of a variety of skin conditions, such as acne, in which topical application is potentially effective. The compositions and methods provided herein address these and other needs in the art.

Dapsone, (4,4'-diaminodiphenyl sulfone) is a medicament possessing several beneficial medicinal activities. Dapsone is typically administered as one of the medicinal agents used in the treatment of leprosy. Dapsone and its derivatives are also effective for treatment of bacterial infections, protozoal infections such as malaria, pneumocystis carinii, and plasmonic infections such as toxoplasmosis.

Dapsone is also useful as an anti-inflammatory agent. It has been used to treat skin diseases characterized by the abnormal infiltration of neutrophils, such as Dermatitis herpetiformis, linear IGA dermatosis, pustular psoriasis, pyoderma gangrenosum, acne vulgaris, and Sweet's Syndrome.

Use of topical compositions of dapsone can be problematic. Topical compositions may act as drying agents for the skin. They remove essential oils and natural skin softeners from the skin thus causing it to be dry, itch and crack. Inclusion of exogenous skin emollients, oils and the like, however, causes phase separation and precipitation of dapsone. Use of typical emulsifiers does not solve the dapsone precipitation owing to the lowered dapsone solubility and conflicting physical characteristics of the phases of the resulting composition. In particular, topical compositions including dapsone and methods are needed that would, for example, exhibit improved effectiveness, reduced side effects, or both, when used in a particular patient with a skin condition. Such improved topical compositions including dapsone and methods of their use are also needed to improve treatment of patients with acne or suspected acne. The present dapsone and dapsone/adapalene compositions can be useful for treating a variety of dermatological conditions. Some useful compositions include dapsone and/or adapalene in a polymeric viscosity builder. Some compositions can be adjusted to optimize the dermal delivery profile of dapsone to effectively treat dermatological conditions and improve the efficiency of pharmaceutical products applied to the skin. Diethylene glycol monoethyl ether is a solubilizer for dapsone, thereby allowing compositions to be prepared with increased solubilized concentrations of dapsone. As a result, the compositions
described herein are effective in treating dermatological conditions in a subject in need thereof.

[0009] Moreover, it has been found that use of a polymeric viscosity builder minimizes the intensity of yellowing of the composition caused by the increased solubility of dapsone in diethylene glycol monoethyl ether. In addition, the polymeric viscosity builder influences dapsone crystallization. This, in turn, results in compositions with improved aesthetics (i.e., reduction in particle size which minimizes “gritty” feeling upon application).

[0010] In one embodiment, there are provided compositions including dapsone, a first solubilizing agent which is diethylene glycol monoethyl ether, optionally at least one second solubilizing agent, a polymeric viscosity builder, and water, wherein the dapsone is present at a concentration of about 5% w/w to about 10% w/w.

[0011] In one embodiment, there are provided compositions including dapsone, a first solubilizing agent which is diethylene glycol monoethyl ether, optionally at least one second solubilizing agent, a polymeric viscosity builder, and water, wherein the dapsone is present at a concentration of about 3% w/w to 8% w/w.

[0012] In another embodiment, there are provided compositions for use in methods for treating a dermatological condition. Such methods can be performed, for example, by administering to a subject in need thereof a therapeutically effective amount of a pharmaceutical composition described herein.

BRIEF DESCRIPTION OF THE FIGURES

[0013] Figure 1 presents the impact of an acrylamide/sodium acryloyldimethyltaurate copolymer emulsion viscosity builder on color change.

Figure 2 presents the impact of an acrylamide/sodium acryloyldimethyltaurate copolymer emulsion viscosity builder on dapsone crystal growth.

Figure 3 presents the impact of anti-oxidants and chelating agents on color change.

DETAILED DESCRIPTION

[0014] It is to be understood that both the foregoing general description and the following detailed description are exemplary and explanatory only and do not restrict the claims. As used herein, the use of the singular includes the plural unless specifically stated otherwise. As used herein, “or” means “and/or” unless stated otherwise. Furthermore, use of the term “including” as well as other forms, such as “includes,” and “included,” is not limiting. The section headings used herein are for organizational purposes only and are not to be construed as limiting the subject matter described.

[0015] Some embodiments include compositions and products for treatment of skin conditions and methods of treating skin conditions. The term “skin condition” as used herein encompasses human and animal conditions, disorders, or diseases affecting skin. Such skin conditions include, but are not limited to, conditions involving skin inflammation, conditions involving sebaceous glands and hair follicles, conditions characterized by acneiform symptoms, and conditions involving skin dryness, skin thickening, skin scaling or skin flaking. Skin conditions that can be treated using some compositions, products and methods described herein include, but are not limited to, acne, rosacea, folliculitis, perioral dermatitis, photodamage, skin aging, psoriasis, ichthyosis, atopic dermatitis, treatment of chronic wounds, bed sores, keratosis pilaris, scars, including surgical and acne scars, sebaceous cysts, inflammatory dermatoses, post inflammatory hyperpigmentation, eczema, xerosis, pruritis, lichen planus, nodular prurigo, eczema, and milliaria.

[0016] The term “acne,” as used herein, encompasses skin conditions involving acneiform or acne-like symptoms. For example, a skin condition characterized by follicular eruptions, such as papules and pustules resembling acne, can be categorized as acne. It is to be understood that the term “acne” is not to be limited to diseases and conditions characterized by papules and pustules, but can be characterized by a variety of symptoms. It is also to be understood that a particular patient having acne can be in remission, or the patient’s acne can be controlled by continuing treatments, and therefore the patient can exhibit reduced symptoms or be asymptomatic. Nevertheless, continuing treatment of acne can be recommended in such a patient in order to reduce the probability of the return of the acne symptoms.

[0017] Symptoms of acne or acne-like conditions include, but are not limited to, the appearance of various skin lesions. The term “lesion” is generally used to denote an infected or diseased patch of skin. A lesion can involve an infected sebaceous gland. Some lesions are more severe than others. Examples of skin lesions are comedones, macules, papules, pustules, nodules and cysts. The term “comedo” (plural “comedones”) is used to describe a sebaceous follicle plugged with dirt, other cells, tiny hairs, or bacteria. Comedones include the so-called “blackheads,” which can also refer to as “open comedones,” which have a spot or a surface that appears black. Comedones also include slightly inflamed, skin colored bumps, as well as “whiteheads,” which have a spot or a surface that appears white. The term “macule” generally refers to a flat spot or area of the skin with a changed color, such as a red spot. The term “pustule” is generally used to refer to an inflamed, pus-filled lesion, or a small inflamed elevation of the skin that is filled with pus. The term “papule” is generally used to refer to a small, solid, usually inflammatory elevation of the skin that does not contain pus.
The term "nodule" is generally used to refer to an elevation of a skin that is similar to a papule but is white and dome-shaped. Colloquially, a papule, a pustule or a nodule can be referred to as "a pimple" or "a zit." The term "cyst" generally refers to an abnormal membranous sac containing a liquid or semi-liquid substance containing white blood cells, dead cells, and bacteria. Cysts can be painful and extend to deeper layers of skin.

In dermatological science and dermatological and cosmetology practice, acne can be classified or categorized into one or more types or categories, according to one or more lines of categorization, such as a predominantly observed type of symptoms, severity of condition or predominant localization. It is to be understood that classification of acne into one of the subtypes does not mean that the characteristics of the classified condition are limited to the symptoms associated with the specific type.

Comedonal acne is characterized by the appearance of non-inflammatory lesions, such as blackheads and whiteheads. Localized cystic acne is characterized by appearance of a few cysts on face, chest and back. Diffuse cystic acne is characterized by the appearance of cysts on wide areas of face, chest and back. Nodular acne is characterized by the appearance of nodules. Nodulocystic acne is characterized by appearance of nodules and cysts. Acne vulgaris is a common form of acne characterized by the appearance of several types of lesions, which may appear together or separately. Individual acne lesions usually last less than two weeks but the deeper papules and nodules may persist for months. Acne vulgaris commonly affects adolescents, but it may also appear, persist or become more severe in adulthood. Acne vulgaris may occur on the face, chest, back and sometimes even more extensively.

Depending on severity, acne can be mild, moderate or severe. Mild acne is generally categorized by the appearance of with blackheads and whiteheads, but can also include papules and pustules. Moderate acne is generally characterized by appearance of more painful, deep-rooted, inflamed lesions, which can result in scarring. Severe acne is characterized by the appearance of deep-rooted inflammatory lesions, including cysts and nodules which can be painful and can produce scarring. Acne conglobata is a category of acne characterized by highly inflammatory cysts that communicate under the skin with abscesses and burrowing sinus tracts.

Other skin conditions exhibiting acne-like symptoms which can be treated by the compositions and methods described herein are discussed below. Pyoderma faciale, also known as rosacea fulminans, is a condition that appears in females and is characterized by abrupt appearance of inflamed cysts and nodules localized on the face. Rosacea, which can be referred to as acne rosacea, is a condition that affects both the skin and the eyes and is characterized by redness, bumps, pimpls, and, in advanced stages, thickened skin on the nose. In some classification systems, rosacea and acne are considered as separate conditions. Rosacea usually occurs on the face, although the neck and upper chest are also sometimes involved. A mild degree of eye (ocular) involvement occurs in more than fifty percent of people with rosacea. Perioral dermatitis is characterized by the appearance of small tiny papules, pustules, red bumps and scaling with intense itching. It is usually localized to the surrounding area of the mouth and on the chin, or extends to involve the eyelids and the forehead. Gram-negative folliculitis is a bacterial infection characterized by the appearance of pustules and cysts, possibly occurring as a complication resulting from a long term antibiotic treatment of acne vulgaris.

As used herein, the terms "treatment" or "treating" in reference to a skin condition generally mean "having positive effect on a skin condition" and encompass alleviation of at least one symptom of a skin condition, a reduction in the severity of the skin conditions, or delay, prevention, or inhibition of the progression of the skin condition. Treatment need not mean that the condition is totally cured. A composition or a product useful for treatment of a skin condition, or a method of treating a skin condition, needs only to reduce the severity of a skin condition, reduce the severity of symptoms associated therewith, provide improvement to a patient's quality of life, or delay, prevent, or inhibit the onset of symptoms of a skin condition.

In one embodiment, there are provided compositions including dapsone, a first solubilizing agent which is diethylene glycol monoethyl ether, optionally at least one second solubilizing agent, a polymeric viscosity builder, and water, wherein the dapsone is present at a concentration of about 5% w/w to about 10% w/w, about 10% w/w to about 10% w/w, about 3% w/w to about 10% w/w, about 3% w/w to about 8% w/w, about 4% w/w to about 6% w/w, or about 5%. In certain embodiments, dapsone is present in the composition at 5.0%, 5.5%, 6.0%, 6.5%, 7.0%, 7.5%, 8.0%, 8.5%, 9.0%, 9.5%, or 10.0% w/w.

The polymeric viscosity builder comprises an acrylamide/sodium acryloyldimethyltaurate copolymer, and may further include isohexadecane, sorbitan oleate, water, and Polysorbate 80. In some embodiments, the polymeric viscosity builder is present at a concentration of about 2% w/w to about 6% w/w. In some embodiments, the polymeric viscosity builder is present at a concentration of about 3% w/w to about 5% w/w. In some embodiments, the polymeric viscosity builder is present in the composition at about 4% w/w.

In some embodiments, diethylene glycol monoethyl ether is present at a concentration of about 25% w/w to about 40% w/w. In some embodiments, diethylene glycol monoethyl ether is present at a concentration of about 30% w/w to about 40% w/w. In some embodiments, diethylene glycol monoethyl ether is present at a concentration of about 35% w/w to about 40% w/w.

In some embodiments, diethylene glycol monoethyl ether is present at a concentration of about 10% w/w to
about 40% w/w, about 20% w/w to about 30% w/w, or about 25%.

[0027] In another embodiment, there are provided compositions further including adapalene. In some embodiments, adapalene is present at a concentration of about 0.1% w/w to about 0.3% w/w.

[0028] In some embodiments, the second solubilizing agent is selected from alcohols, glycols, esters, ethers, or silicones. Such second solubilizing agents include, but are not limited to, PEG 400, lactic acid, dimethyl isosorbide, propylene glycol, propylene carbonate, hexylene glycol, isostearyl alcohol, benzyl alcohol, diethyl sebacate, and ethanol.

[0029] In certain embodiments, the second solubilizing agent is propylene glycol. In some embodiments, propylene glycol is present at a concentration of about 2% w/w to 8% w/w. In some embodiments, propylene glycol is present at a concentration of about 3% w/w to 7% w/w. In some embodiments, propylene glycol is present in the composition at about 5% w/w.

[0030] In certain embodiments, the second solubilizing agent is propylene carbonate. In some embodiments, propylene carbonate is present at a concentration of about 2% w/w to 8% w/w. In some embodiments, propylene carbonate is present at a concentration of about 3% w/w to 7% w/w. In some embodiments, propylene carbonate is present in the composition at about 5% w/w.

[0031] In certain embodiments, the second solubilizing agent is ethanol. In some embodiments, ethanol is present at a concentration of about 1% w/w to about 5% w/w. In some embodiments, ethanol is present at a concentration of about 2% w/w to about 4% w/w. In some embodiments, ethanol is present in the composition at about 3% w/w.

[0032] In some embodiments, the compositions further include methyl paraben.

[0033] In other embodiments, the compositions further include carbomer homopolymer type C. In some embodiments, carbomer homopolymer type C is present at a concentration of about 0.7% w/w to about 1.5% w/w. In other embodiments, carbomer homopolymer type C is present at a concentration of about 0.85% w/w to about 1.0% w/w.

[0034] In some embodiments, the compositions further include a neutralizing agent. In certain embodiments, the neutralizing agent is an ionic or amine buffer. In certain embodiments, the neutralizing agent is sodium hydroxide or triethanolamine. Use of a neutralizing agent results in compositions typically having a pH from 5.5 to 6.5.

[0035] In some embodiments, the compositions further include a chelating agent. In some embodiments, the chelating agent is ethylene diamine tetraacetic acid (EDTA). EDTA is typically present in the compositions from about 0.02% w/w to about 0.04% w/w. In certain embodiments, EDTA is present in the compositions at about 0.03% w/w.

[0036] Compositions described herein are typically in the form of a gel, an emulsion, a cream, a liquid, a paste, a lotion, a nanoemulsion, a microemulsion, a reverse emulsion, or a liposomal cream.

EMBODIMENTS

[0037] The following embodiments are specifically contemplated herein.

Embodiment 1. A composition comprising dapsone, a first solubilizing agent which is diethylene glycol monoethyl ether, optionally at least one second solubilizing agent, a polymeric viscosity builder, comprising acrylamide/sodium acryloyldimethyltaurate copolymer water, wherein the dapsone is present in the composition at a concentration of 3% w/w to 10% w/w.

Embodiment 2. The composition of embodiment 1, wherein the diethylene glycol monoethyl ether is present at a concentration of about 10% w/w to about 40% w/w.

Embodiment 3. The composition of embodiment 1, wherein the diethylene glycol monoethyl ether is present at a concentration of about 20% w/w to about 30% w/w.

Embodiment 4. The composition of embodiment 1, wherein the diethylene glycol monoethyl ether is present in the composition at a concentration of about 25% w/w.

Embodiment 5. The composition of embodiment 1, further comprising adapalene.

Embodiment 6. The composition of embodiment 5, wherein the adapalene is present at a concentration of about 0.1% w/w to about 0.3% w/w.

Embodiment 7. The composition of embodiment 1 wherein the second solubilizing agent is selected an alcohol, a glycol, an ester, or an ether.

Embodiment 8. The composition of embodiment 1, wherein the second solubilizing agent is PEG 400, lactic acid, dimethyl isosorbide, propylene glycol, propylene carbonate, hexylene glycol, isostearyl alcohol, diethyl sebacate,
or ethanol.

Embodiment 9. The composition of embodiment 8, wherein the second solubilizing agent is propylene glycol.

Embodiment 10. The composition of embodiment 9, wherein the propylene glycol is present in the composition at a concentration of about 5% w/w.

Embodiment 11. The composition of embodiment 8, wherein the second solubilizing agent is propylene carbonate.

Embodiment 12. The composition of embodiment 11, wherein the propylene carbonate is present in the composition at a concentration of about 5% w/w.

Embodiment 13. The composition of embodiment 8, wherein the second solubilizing agent is ethanol.

Embodiment 14. The composition of embodiment 13, wherein the ethanol is present in the composition at a concentration of about 3% w/w.

Embodiment 15. The composition of embodiment 1, wherein the polymeric viscosity builder comprises an acrylamide/sodium acryloyldimethyltaurate copolymer.

Embodiment 16. The composition of embodiment 1, wherein the polymeric viscosity builder is present at a concentration of about 2% w/w to about 6% w/w.

Embodiment 17. The composition of embodiment 1, wherein the polymeric viscosity builder is present at a concentration of about 4% w/w.

Embodiment 18. The composition of embodiment 1, further comprising methyl paraben.

Embodiment 19. The composition of embodiment 1, further comprising Carbomer interpolymer type A, Carbomer interpolymer type B, or Carbomer Homopolymer Type C.

Embodiment 20. The composition of embodiment 19, wherein the Carbomer Homopolymer Type C is present at a concentration of about 0.7% w/w to about 1.5% w/w.

Embodiment 21. The composition of embodiment 19, wherein the Carbomer Homopolymer Type C is present at a concentration of about 0.85% w/w to about 1.5% w/w.

Embodiment 22. The composition of embodiment 19, wherein the Carbomer interpolymer Type A is present at a concentration of about 1% w/w to 2% w/w.

Embodiment 23. The composition of embodiment 19, wherein the Carbomer interpolymer Type B is present at a concentration of about 0.1% w/w to about 0.5% w/w.

Embodiment 24. The composition of embodiment 1, further comprising a neutralizing agent.

Embodiment 25. The composition of embodiment 24 wherein the neutralizing agent is NaOH or triethanolamine.

Embodiment 26. The composition of embodiment 1 further comprising a chelating agent.

Embodiment 27. The composition of embodiment 26, wherein the chelating agent is ethylene diamine tetraacetic acid.

Embodiment 28. The composition of embodiment 27, wherein the ethylene diamine tetraacetic acid is present at a concentration of about 0.02% w/w to about 0.04% w/w.

Embodiment 29. The composition of embodiment 27, wherein the ethylene diamine tetraacetic acid is present in the composition at about 0.03% w/w.

Embodiment 30. The composition of embodiment 1 wherein the composition is in the form of a gel, a suspension,
an emulsion, a cream, a liquid, a paste, a lotion, a nanoemulsion, a microemulsion, a reverse emulsion, or a liposomal cream.

Embodiment 31. A composition of embodiment 1 for use in a method for treating a dermatological condition comprising administering to a subject in need thereof a therapeutically effective amount of a composition of embodiment 1.

Embodiment 32. The composition of embodiment 31 wherein the condition is *acne vulgaris*, rosacea, atopic dermatitis, treatment of chronic wounds, bed sores, keratosis pilaris, sebaceous cysts, inflammatory dermatoses, post inflammatory hyperpigmentation, eczema, xerosis, pruritis, lichen planus, nodular prurigo, dermatitis, eczema, or miliaria.

Embodiment 33. The composition of embodiment 32 wherein the condition is *acne vulgaris*.

Embodiment 34. The composition of embodiment 1, 2, 3, or 4, further comprising adapalene.

Embodiment 35. The composition of embodiment 34, wherein the adapalene is present at a concentration of about 0.1% w/w to about 0.3% w/w.

Embodiment 36. The composition of embodiment 1, 2, 3, 4, 34, or 35, wherein the second solubilizing agent is selected an alcohol, a glycol, an ester, or an ether.

Embodiment 37. The composition of embodiment 1, 2, 3, 4, 34, 35, or 36, wherein the second solubilizing agent is PEG 400, lactic acid, dimethyl isosorbide, propylene glycol, propylene carbonate, hexylene glycol, isoctearyl alcohol, diethyl sebacate, or ethanol.

Embodiment 38. The composition of embodiment 37, wherein the second solubilizing agent is propylene glycol.

Embodiment 39. The composition of embodiment 38, wherein the propylene glycol is present in the composition at a concentration of about 5% w/w.

Embodiment 40. The composition of embodiment 37, wherein the second solubilizing agent is propylene carbonate.

Embodiment 41. The composition of embodiment 40, wherein the propylene carbonate is present in the composition at a concentration of about 5% w/w.

Embodiment 42. The composition of embodiment 37, wherein the second solubilizing agent is ethanol.

Embodiment 43. The composition of embodiment 42, wherein the ethanol is present in the composition at a concentration of about 3% w/w.

Embodiment 44. The composition of embodiment 1, 2, 3, 4, 34, 35, 36, 37, 38, 39, 40, 41, 42, or 43, wherein the polymeric viscosity builder comprises an acrylamide/sodium acryloyldimethyltaurate copolymer.

Embodiment 45. The composition of embodiment 1, 2, 3, 4, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, or 44, wherein the polymeric viscosity builder is present at a concentration of about 2% w/w to about 6% w/w.

Embodiment 46. The composition of embodiment 45, wherein the polymeric viscosity builder is present at a concentration of about 4% w/w.

Embodiment 47. The composition of embodiment 1, 2, 3, 4, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, or 46, further comprising methyl paraben.

Embodiment 48. The composition of embodiment 1, 2, 3, 4, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, or 47, further comprising Carbomer interpolymer type A, Carbomer interpolymer type B, or Carbomer Homopolymer Type C.

Embodiment 49. The composition of embodiment 48, wherein the Carbomer Homopolymer Type C is present at a concentration of about 0.7% w/w to about 1.5% w/w.
Embodiment 50. The composition of embodiment 48, wherein the Carbomer Homopolymer Type C is present at a concentration of about 0.85% w/w to about 1.5% w/w.

Embodiment 51. The composition of embodiment 48, wherein the Carbomer interpolymer Type A is present at a concentration of about 1% w/w to 2% w/w. Embodiment 52. The composition of embodiment 48, wherein the Carbomer interpolymer Type B is present at a concentration of about 0.1% w/w to about 0.5% w/w.

Embodiment 53. The composition of embodiment 1, 2, 3, 4, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, or 52, further comprising a neutralizing agent.

Embodiment 54. The composition of embodiment 53 wherein the neutralizing agent is NaOH or triethanolamine.

Embodiment 55. The composition of embodiment 1, 2, 3, 4, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, or 54, further comprising a chelating agent.

Embodiment 56. The composition of embodiment 55, wherein the chelating agent is ethylene diamine tetraacetic acid.

Embodiment 57. The composition of embodiment 56, wherein the ethylene diamine tetraacetic acid is present at a concentration of about 0.02% w/w to about 0.04% w/w.

Embodiment 58. The composition of embodiment 56, wherein the ethylene diamine tetraacetic acid is present in the composition at about 0.03% w/w.

Embodiment 59. The composition of embodiment 1, 2, 3, 4, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, or 58, wherein the composition is in the form of a gel, a suspension, an emulsion, a cream, a liquid, a paste, a lotion, a nanoemulsion, a microemulsion, a reverse emulsion, or a liposomal cream.

Embodiment 60. A composition according to the present invention for use in a method for treating a dermatological condition comprising administering to a subject in need thereof a therapeutically effective amount of a composition of embodiment 1, 2, 3, 4, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, or 59.

Embodiment 61. A composition of embodiment 60 wherein the condition is acne vulgaris, rosacea, atopic dermatitis, treatment of chronic wounds, bed sores, keratoses pilaris, sebaceous cysts, inflammatory dermatoses, post inflammatory hyperpigmentation, eczema, xerosis, pruritis, lichen planus, nodular prurigo, dermatitis, eczema, or miliaria.

Embodiment 62. A composition of embodiment 60 wherein the condition is acne vulgaris.

[0038] The following examples are intended only to illustrate the some embodiments and should in no way be construed as limiting the claims.

EXAMPLES

Example 1

[0039] Table 1 lists two formulations (containing equivalent levels of diethylene glycol monoethyl ether) that show the impact of acrylamide / sodium acryloyldimethyltaurate copolymer based thickener on dapsone particle size. Figure 2 presents impact of acrylamide / sodium acryloyldimethyltaurate copolymer based thickener on dapsone crystal growth. The microscopic image of ENA (30% diethylene glycol monoethyl ether, 4% acrylamide / sodium acryloyldimethyltaurate copolymer based thickener) in comparison to ENC (30% diethylene glycol monoethyl ether, 1% Carbopol 980) shows a clear difference in particle size of the dapsone. Larger crystals were observed in the sample with carbomer homopolymer type C (ENC vs. ENA).

<table>
<thead>
<tr>
<th>Formulation #</th>
<th>ENA</th>
<th>ENC</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dapsone</td>
<td>7.5</td>
<td>7.5</td>
</tr>
</tbody>
</table>
Example 2

[0040] Example compositions contemplated for use as described herein are set forth in Table 2 below:

<table>
<thead>
<tr>
<th>Composition #</th>
<th>1</th>
<th>2</th>
<th>3</th>
<th>4</th>
<th>5</th>
<th>6</th>
<th>7</th>
<th>8</th>
<th>9</th>
<th>10</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dapsone</td>
<td>5-10</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Adapalene</td>
<td>---</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>0.1-0.3</td>
</tr>
<tr>
<td>Diethylene glycol monoethyl ether</td>
<td>30</td>
<td>35</td>
<td>40</td>
<td>30</td>
<td>35</td>
<td>30</td>
<td>35</td>
<td>40</td>
<td>30</td>
<td>35</td>
</tr>
<tr>
<td>Carborner homopolymer type C</td>
<td>---</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>0.85-1.5</td>
<td>---</td>
<td>---</td>
<td>---</td>
</tr>
<tr>
<td>Acrylamide/sodium acryloyldimethyltaurate copolymer emulsion</td>
<td>4</td>
<td>---</td>
<td>4</td>
<td>---</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Methyl paraben</td>
<td>0.2</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>NaOH/ pH adjusting solution</td>
<td>pH 5.5-6.5</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Purified Water</td>
<td>Q.S 100</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Example 3

[0041] Anti-oxidants and chelating agents such as sodium metabisulfite, citric acid and EDTA were added to formulations to help slow down or completely stop any impurity formation. Table 3 presents the composition of formulations tested. Formulation A7 with sodium metabisulfite minimized the intensity of yellow color caused by the increased solubility of dapsone in diethylene glycol monoethyl ether and maintained the low color intensity over time at accelerated condition (40°C). See Figure 3 for appearance of the formulations over 4 weeks. Table 4 presents the formulation panel summarizing other formulation options with chelating agents and antioxidants.

Table 3. Compositions Tested containing Antioxidants or Chelating Agents

<table>
<thead>
<tr>
<th>Composition #</th>
<th>A5</th>
<th>A6</th>
<th>A7</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dapsone</td>
<td>7.5</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Diethylene glycol monoethyl ether</td>
<td>35</td>
<td>40</td>
<td>35</td>
</tr>
<tr>
<td>Carborner homopolymer type C</td>
<td>1.25</td>
<td>---</td>
<td>1.25</td>
</tr>
<tr>
<td>Acrylamide/sodium acryloyldimethyltaurate copolymer emulsion</td>
<td>---</td>
<td>4</td>
<td>---</td>
</tr>
<tr>
<td>EDTA</td>
<td>0.05</td>
<td>---</td>
<td></td>
</tr>
<tr>
<td>Anhydrous Citric Acid</td>
<td>0.1</td>
<td>---</td>
<td></td>
</tr>
<tr>
<td>Sodium Metabisulfite</td>
<td>---</td>
<td>0.2</td>
<td></td>
</tr>
<tr>
<td>Methyl paraben</td>
<td>0.17</td>
<td>0.2</td>
<td></td>
</tr>
<tr>
<td>Propyl paraben</td>
<td>0.03</td>
<td>---</td>
<td></td>
</tr>
</tbody>
</table>
Table 4. Formulation panel summarizing other formulation options

<table>
<thead>
<tr>
<th>Composition #</th>
<th>1</th>
<th>2</th>
<th>3</th>
<th>4</th>
<th>5</th>
<th>6</th>
<th>7</th>
<th>8</th>
<th>9</th>
<th>10</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dapsone</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>5-10</td>
</tr>
<tr>
<td>Adapalene</td>
<td>---</td>
<td>---</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>0.1-0.3</td>
<td></td>
</tr>
<tr>
<td>Diethylene glycol monoethyl ether</td>
<td>30</td>
<td>35</td>
<td>40</td>
<td>30</td>
<td>35</td>
<td>30</td>
<td>35</td>
<td>40</td>
<td>30</td>
<td>35</td>
</tr>
<tr>
<td>carbomer homopolymer type C</td>
<td>---</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>0.85-1.5</td>
<td></td>
<td></td>
<td>0.85-1.5</td>
<td></td>
</tr>
<tr>
<td>Acrylamide/sodium Acryloyl dimethyltaurate copolymer emulsion</td>
<td>4</td>
<td>---</td>
<td></td>
<td></td>
<td>4</td>
<td></td>
<td></td>
<td>---</td>
<td></td>
<td></td>
</tr>
<tr>
<td>EDTA</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>0-0.1</td>
</tr>
<tr>
<td>Citric Acid</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>0-0.1</td>
</tr>
<tr>
<td>Sodium Metabisulfite</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>0-0.5</td>
</tr>
<tr>
<td>Methyl paraben</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>0.2</td>
</tr>
<tr>
<td>NaOH/ pH adjusting solution</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>pH 5.5-6.5</td>
</tr>
<tr>
<td>Purified Water</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Q.S 100</td>
</tr>
</tbody>
</table>

Example 4

[0042] Additional example compositions contemplated for use as described herein are set forth in Table 5 below.

Table 5 Additional examples containing alternate neutralizer

<table>
<thead>
<tr>
<th>Materials</th>
<th>% w/w</th>
<th>5-1</th>
<th>5-2</th>
<th>5-3</th>
<th>5-4</th>
<th>5-5</th>
<th>5-6</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dapsone</td>
<td></td>
<td>7.5</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Adapalene</td>
<td>---</td>
<td>0.3</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>---</td>
</tr>
<tr>
<td>Diethylene glycol monoethyl ether</td>
<td>30</td>
<td>35</td>
<td>40</td>
<td>30</td>
<td>40</td>
<td>25</td>
<td></td>
</tr>
<tr>
<td>carbomer homopolymer type C</td>
<td></td>
<td>1</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Methylparaben</td>
<td></td>
<td>0.2</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Triethanolamine (TEA) Q.S.</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>pH 5.5-6.5</td>
</tr>
<tr>
<td>Hydrochloric Acid Q.S.</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>pH 5.5-6.5</td>
</tr>
<tr>
<td>Purified Water</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>q.s.a.d.100</td>
</tr>
</tbody>
</table>

Example 4

[0043] Additional example compositions contemplated for use as described herein are set forth in Table 6 below.
### Table 6 Additional examples (containing co-solvents, stabilizer and alternate thickener)

<table>
<thead>
<tr>
<th>Materials</th>
<th>% w/w</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>6-1</td>
</tr>
<tr>
<td>Dapsone</td>
<td>7.5</td>
</tr>
<tr>
<td>Adapalene</td>
<td>--</td>
</tr>
<tr>
<td>Diethylene glycol monoethyl ether</td>
<td>25</td>
</tr>
<tr>
<td>Propylene glycol</td>
<td>5</td>
</tr>
<tr>
<td>Propylene Carbonate</td>
<td>5</td>
</tr>
<tr>
<td>Ethanol (absolute)</td>
<td>3</td>
</tr>
<tr>
<td>EDTA</td>
<td>0.03</td>
</tr>
<tr>
<td>Carbomer Interpolymer Type A</td>
<td>--</td>
</tr>
<tr>
<td>Carbomer Interpolymer Type B</td>
<td>--</td>
</tr>
<tr>
<td>Acrylamide/sodium acryloyldimethyltaurate copolymer emulsion</td>
<td>4</td>
</tr>
<tr>
<td>Methyl Paraben</td>
<td></td>
</tr>
<tr>
<td>Triethanolamine</td>
<td></td>
</tr>
<tr>
<td>Purified Water</td>
<td></td>
</tr>
</tbody>
</table>

**Example 5**

Another useful composition is depicted in Table 7.

### Table 7

<table>
<thead>
<tr>
<th>Ingredient</th>
<th>Amount (% w/w)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dapsone</td>
<td>5-8</td>
</tr>
<tr>
<td>Adapalene</td>
<td>0.1-0.3</td>
</tr>
<tr>
<td>Diethylene glycol monoethyl ether</td>
<td>40.00</td>
</tr>
<tr>
<td>Propylene glycol</td>
<td>5.00</td>
</tr>
<tr>
<td>Ethanol (absolute)</td>
<td>3.00</td>
</tr>
<tr>
<td>Ethylene Diamine Tetraacetic acid (EDTA)</td>
<td>0.03</td>
</tr>
<tr>
<td>Methyl Paraben</td>
<td>0.20</td>
</tr>
<tr>
<td>Sepineo P 600</td>
<td>4.00</td>
</tr>
<tr>
<td>Purified Water</td>
<td>Q.S.</td>
</tr>
</tbody>
</table>

**Example 6**

Another useful composition is depicted in Table 8.

### Table 8

<table>
<thead>
<tr>
<th>Ingredient</th>
<th>Amount (% w/w)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dapsone</td>
<td>5.0</td>
</tr>
<tr>
<td>Diethylene glycol monoethyl ether</td>
<td>25</td>
</tr>
<tr>
<td>Methyl Paraben</td>
<td>0.2</td>
</tr>
</tbody>
</table>
Claims

1. A composition comprising dapsone, a first solubilizing agent which is diethylene glycol monoethyl ether, optionally at least one second solubilizing agent, a polymeric viscosity builder, and water, wherein the dapsone is present in the composition at a concentration of 3% w/w to 10% w/w, wherein the polymeric viscosity builder comprises an acrylamide/sodium acryloyldimethyltaurate copolymer.

2. The composition of claim 1, wherein the diethylene glycol monoethyl ether is present at a concentration of 20% w/w to 30% w/w, preferably at a concentration of 25% w/w.

3. The composition of claim 1, further comprising adapalene, optionally at a concentration of 0.1% w/w to 0.3% w/w.

4. The composition of claim 1, wherein the second solubilizing agent is PEG 400, lactic acid, dimethyl isosorbide, propylene glycol, propylene carbonate, hexylene glycol, isostearyl alcohol, diethyl sebacate, or ethanol.

5. The composition of claim 1, wherein the second solubilizing agent is propylene glycol.

6. The composition of claim 1, wherein the second solubilizing agent is propylene carbonate.

7. The composition of claim 1, wherein the second solubilizing agent is ethanol.

8. The composition of claim 1, wherein the polymeric viscosity builder is present at a concentration of 2% w/w to 6% w/w, preferably at a concentration of 4% w/w.

9. The composition of claim 1, further comprising methyl paraben.

10. The composition of claim 1, further comprising Carbomer interpolymer type A, Carbomer interpolymer type B, or Carbomer Homopolymer Type C.

11. The composition of claim 1, further comprising a neutralizing agent, wherein the neutralizing agent is preferably NaOH or triethanolamine.

12. The composition of claim 1 further comprising ethylene diamine tetraacetic acid.

13. The composition of claim 1 for use in a method for treating a dermatological condition comprising administering to a subject in need thereof a therapeutically effective amount of the composition.

14. The composition for use according to claim 13, wherein the condition is acne vulgaris, rosacea, atopic dermatitis, treatment of chronic wounds, bed sores, keratosis pilaris, sebaceous cysts, inflammatory dermatoses, post inflammatory hyperpigmentation, eczema, xerosis, pruritis, lichen planus, nodular prurigo, dermatitis, eczema, or miliaria, and wherein the condition is preferably acne vulgaris.

Patentansprüche

1. Zusammensetzung, die Dapson, ein erstes solubilisierendes Mittel, das Diethyenglykolmonoethylether ist, gegebenenfalls wenigstens ein zweites solubilisierendes Mittel, einen polymeren Viskositätsbildner und Wasser umfasst, wobei das Dapson in der Zusammensetzung bei einer Konzentration von 3% G/G bis 10% G/G vorliegt, wobei der
polymere Viskositätsbildner ein
Acrylamid/Natriumacryloyldimethyltaurat-Copolymer umfasst.


3. Zusammensetzung gemäß Anspruch 1, die weiterhin Adapalen, gegebenenfalls bei einer Konzentration von 0,1% G/G bis 0,3% G/G, umfasst.

4. Zusammensetzung gemäß Anspruch 1, wobei das zweite solubilisierende Mittel PEG 400, Milchsäure, Dimethylsorbid, Propylenglykol, Propylencarbonat, Hexylenglykol, Isostearylalkohol, Diethylsebacat oder Ethanol ist.

5. Zusammensetzung gemäß Anspruch 1, wobei das zweite solubilisierende Mittel Propylenglykol ist.

6. Zusammensetzung gemäß Anspruch 1, wobei das zweite solubilisierende Mittel Propylencarbonat ist.

7. Zusammensetzung gemäß Anspruch 1, wobei das zweite solubilisierende Mittel Ethanol ist.


9. Zusammensetzung gemäß Anspruch 1, die weiterhin Methylparaben umfasst.


11. Zusammensetzung gemäß Anspruch 1, die weiterhin ein neutralisierendes Mittel umfasst, wobei das neutralisierende Mittel vorzugsweise NaOH oder Triethanolamin ist.

12. Zusammensetzung gemäß Anspruch 1, die weiterhin Ethylen diamintetraessigsäure umfasst.

13. Zusammensetzung gemäß Anspruch 1 zur Verwendung bei einem Verfahren zur Behandlung eines dermatologischen Zustands, umfassend das Verabreichen einer therapeutisch wirksamen Menge der Zusammensetzung an ein Subjekt, das dessen bedarf.


Revendications

1. Composition comprenant de la dapsone, un premier agent solubilisant qui est l'éther monoéthyléthyl glycol, éventuellement au moins un deuxième agent solubilisant, un constructeur de viscosité polymère, et de l'eau, dans laquelle la dapsone est présente dans la composition à une concentration de 3 % p/p à 10 % p/p, dans laquelle le constructeur de viscosité polymère comprend un copolymère d'acrylamide/acryloyldimethyltaurate de sodium.

2. Composition selon la revendication 1, dans laquelle l'éther monoéthyléthyl glycol est présent à une concentration de 20 % p/p à 30 % p/p, de préférence à une concentration de 25 % p/p.

3. Composition selon la revendication 1, comprenant en outre de l'adapalène, éventuellement à une concentration de 0,1 % p/p à 0,3 % p/p.

4. Composition selon la revendication 1, dans laquelle le deuxième agent solubilisant est le PEG 400, l'acide lactique, l'isosorbide de diméthyle, le propylène glycol, le carbonate de propylène, l'hexylène glycol, l'alcool isostéarylique, le sébacate de diéthyle, ou l'éthanol.
5. Composition selon la revendication 1, dans laquelle le deuxième agent solubilisant est le propylène glycol.

6. Composition selon la revendication 1, dans laquelle le deuxième agent solubilisant est le carbonate de propylène.

7. Composition selon la revendication 1, dans laquelle le deuxième agent solubilisant est l'éthanol.

8. Composition selon la revendication 1, dans laquelle le constructeur de viscosité polymère est présent à une concentration de 2 % p/p à 6 % p/p, de préférence à une concentration de 4 % p/p.

9. Composition selon la revendication 1, comprenant en outre du méthyle de parabène.

10. Composition selon la revendication 1, comprenant en outre un type A d'interpolymère de carbomère, un type B d'interpolymère de carbomère, ou un type C d'homopolymère de carbomère.

11. Composition selon la revendication 1, comprenant en outre un agent de neutralisation, dans lequel l'agent de neutralisation est de préférence le NaOH ou la triéthanolamine.

12. Composition selon la revendication 1 comprenant en outre de l'acide éthylène diamine tétra-acétique.

13. Composition selon la revendication 1 pour une utilisation dans une méthode de traitement d'une pathologie dermatologique comprenant l'administration à un sujet en ayant besoin d'une quantité thérapeutiquement efficace de la composition.

14. Composition pour une utilisation selon la revendication 13, dans laquelle la pathologie est l'acné vulgaire, la rosacée, la dermatite atopique, le traitement des plaies chroniques, les plaies de lit, la kératose pilaire, les kystes sébacés, les dermatoses inflammatoires, l'hyperpigmentation post-inflammatoire, l'eczéma, la xérose, le prurit, le lichen plan, le prurigo nodulaire, la dermatite, l'eczéma ou la miliaria, et dans laquelle la pathologie est de préférence l'acné vulgaire.
Appearance of formulations following 4 weeks of storage

A1 at initial timepoint

A2 at initial timepoint

A1 after 4 weeks storage at 25°C

A2 after 4 weeks storage at 25°C

A1 after 4 weeks storage at 40°C

A2 after 4 weeks storage at 40°C

Figure 1
Polarized light images of dapsone in suspension formulations

Figure 2
Appearance of formulations with antioxidants or chelating agents over 4 weeks

A5 at Initial timepoint

A6 at Initial timepoint

A7 at Initial timepoint

A5 after 4 weeks storage at 40 °C

A6 after 4 weeks storage at 40 °C

A7 after 4 weeks storage at 40 °C

Figure 3
Topikális dapsont és dapsont/adapalen készítmények és alkalmazási eljárások

Szabadalmi igénypontok

1. Dapsont, egy első szolubilizáló szert, mely dietilenglikol monoetiléter, adott esetben legalább egy második szolubilizáló szert, egy polimer viszkozitást felépítő szert, és vizet tartalmazó készítmény, ahol a dapsont a készítményben 3 tömeg/tömeg% - 10 tömeg/tömeg% koncentrációban van jelen, ahol a polimer viszkozitást felépítő szer egy akrilamid/nátrium akriloil-dimetiltaurát kopolímer.

2. Az 1. igénypont szerinti készítmény, ahol a dietilenglikol monoetiléter 20 tömeg/tömeg% - 30 tömeg/tömeg% koncentrációban, előnyösen 25 tömeg/tömeg% koncentrációban van jelen.

3. Az 1. igénypont szerinti készítmény, mely továbbá adapalent is tartalmaz, adott esetben 0.1 tömeg/tömeg% - 0.3 tömeg/tömeg% koncentrációban.

4. Az 1. igénypont szerinti készítmény, ahol a második szolubilizáló szer PEG 400, tejsav, dimetil-izoszorbid, propilenglikol, propilénkarbonát, hexilenglikol, izosztearilalkohol, dietilszebacát vagy etanol.

5. Az 1. igénypont szerinti készítmény, ahol a második szolubilizáló szer propilenglikol.

6. Az 1. igénypont szerinti készítmény, ahol a második szolubilizáló szer propilénkarbonát.

7. Az 1. igénypont szerinti készítmény, ahol a második szolubilizáló szer etanol.

8. Az 1. igénypont szerinti készítmény, ahol a polimer viszkozitást felépítő szer 2 tömeg/tömeg% - 6 tömeg/tömeg% koncentrációban, előnyösen 4 tömeg/tömeg % koncentrációban van jelen.

9. Az 1. igénypont szerinti készítmény, mely továbbá metilparabént is tartalmaz.
10. Az 1. igénypont szerinti készítmény, mely továbbá Carbomer interpolymer A-t, Carbomer interpolymer B-t, vagy Carbomer Homopolymer C-t tartalmaz.

11. Az 1. igénypont szerinti készítmény, mely továbbá egy semlegesítőszert is tartalmaz, ahol a semlegesítőszer előnyösen NaOH vagy trietanolamin.


13. Az 1. igénypont szerinti készítmény, dermatológiai állapot kezelési eljárásban történő alkalmazásra, melynek során a készítmény hatásos mennyiségét egy arra szoruló alanynak adagoljuk.